Industry Spotlight: Finch Therapeutics
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs.
The company is currently developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.
Autism spectrum disorder
The company is currently developing FIN-211, an orally administered microbiome product candidate for the treatment of children with autism and serious gastrointestinal symptoms.
- Oral delivery of a complete microbiome community that is enriched with targeted microbes
- Designed to address GI and behavioral symptoms by targeting multiple ASD-relevant pathways
- Development program builds off mechanistic data and five investigator-sponsored, proof-of-concept clinical studies showing improvement in both GI and behavioral symptoms following microbiota transplantation
FIN-211 is currently in the pre-clinical development phase, meaning that clinical (in-human) trials to evaluate safety and efficacy have not yet started. When additional information is available about our trial plans, it will be shared on company website.Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.